A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " ChemPartner PharmaTech Co., Ltd.

ChemPartner PharmaTech Co., Ltd.

ChemPartner PharmaTech Co., Ltd. is a CRO that provides a wide range of support from early drug discovery to non-clinical development, and this report examines and summarizes the company's features, disease models it possesses, case studies, and other information.

Features of ChemPartner PharmaTech Co., Ltd.'s Contract Non-clinical Trial Services

Strengths in exploratory toxicology and biologics discovery

In addition to its headquarters in China, ChemPartner PharmaTech Co., Ltd. is based in San Francisco, USA,Strengths in chemistry, biology, pharmacology, DMPK (pharmacokinetics, metabolism), and exploratory toxicology and biologics discoveryWe are a global CRO (contract research organization) with

Along with providing services as a CRO, the company also serves as a partner to pharmaceutical and biotech companies to help them progress their projects. The company employs over 1,500 experienced scientists and pharmaceutical industry leaders educated in Europe and the United States to provide research and development services.

Support drug discovery and development programs

ChemPartner PharmaTech Co., Ltd.'s DMPK division has conducted over 80,000 ADME profiling and more than 50,000 exploratory toxicology studies since its establishment in 2007,Support drug discovery and development programs at partners worldwideThe company is a leading provider of services to the pharmacokinetic clientele. The company also provides services to pharmacokinetic clients.

Provision of IND application packages

The company has integrated DMPK/toxicity data to meet US FDA and NMPA regulatory requirements.IND application package providedWe are committed to Based on the hundreds of FDA filings we have handled, we provide strong support to our clients by preparing reports that meet the rigorous standards required by regulatory authorities (GLP/GCLP compliant ADMET packages).

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

An example of ChemPartner PharmaTech Co., Ltd.'s disease state model

The company offers a variety of in vivo disease models in the immunology and inflammation areas. For example, the company has developed theAdjuvant-induced arthritis (AIA) model in ratsThere is a In this model, female Lewis rats (weighing 180-200 g) are used to induce arthritis with CFA and to evaluate drug efficacy against human rheumatoid arthritis. In addition, BALB/c mice are used to evaluate inflammation and immune responseCon A-induced systemic inflammation modelWe also offer

ChemPartner PharmaTech Co., Ltd.'s non-clinical case studies

In vitro efficacy study using an in vivo xenograft model

This is a case study in which the company's antibody-drug conjugate (ADC), trastuzumab DM1 (T-DM1; a biosimilar of Cadusaila®), was synthesized and tested for in vitro efficacy in a xenograft model. In this case study,Study ADC formulation well tolerated at study dosesIt has been reported that

Reference: ChemPartner PharmaTech Co., Ltd. official website (https://chempartner.com/services/case-study-on-t-dm1-kadcyla/)

ChemPartner PharmaTech Co., Ltd. Company Information

In addition to its Shanghai headquarters, ChemPartner PharmaTech Co., Ltd., based in San Francisco, provides a wide range of support services from early drug discovery to non-clinical development. One of our unique features is that we provide support for the preparation of IND application packages based on our extensive experience.

Address	1F & 3F, Block A, 2829 JinKe Road Zhangjiang Hi-Tech Park Pudong Shanghai, 201203, CN
Tel	+86 21 5132 0088
Website	https://chempartner.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us